Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, ...

Here, we explored how NMDARs signal in tLTD. We found that, regardless of frequency, L5 PC→PC tLTD relies on the non-ionotropic preNMDAR signaling pathway mediated by JNK2, which helps to resolve the ...

The extracellular domain of HER2 is unable to bind extracellular ligands and depends on heterodimerization with other ligand-activated receptors like EGFR ... HER2 tyrosine kinases that has ...

The B7-33 peptide, a derivative of the H2-relaxin hormone, has garnered attention in scientific research due to its potential ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Researchers found a protein that's essential for an enterovirus to enter human cells. Although not the infamous example—that ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

The data convincingly show that the transcription factor Sp1 regulates ephrin-mediated axon guidance in the spinal cord. Although the authors show that Sp1 and its co-activators p300 and CBP are ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.